-
MODELING CURE WITHIN HEALTH ECONOMIC MODELS: A FRAMEWORK TO SUPPORT HEALTH TECHNOLOGY ASSESSMENT BODIES AND MANUFACTURERS
Aug 11, 2026, 17:15 PM -
ENHANCING AMCP DOSSIER DEVELOPMENT THROUGH MULTIMODAL GENERATIVE AI INTERPRETATION OF TABLES, FIGURES, AND GRAPHS
Aug 11, 2026, 17:15 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH NEUTROPENIA/LEUKOPENIA-RELATED HOSPITALIZATIONS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING VALGANCICLOVIR PROPHYLAXIS IN GERMANY: A CLAIMS DATABASE STUDY
Aug 11, 2026, 17:15 PM -
PHARMACEUTICAL DATA EXCLUSIVITY IN CHINA COMPARED WITH INTERNATIONAL STANDARDS
Aug 11, 2026, 17:15 PM -
BEYOND TRIAL AND ERROR: QUANTIFYING THE IMPACT OF MANAGED ENTRY AGREEMENTS FOR ATIDARSAGENE AUTOTEMCEL AS A REAL-WORLD CASE STUDY
Aug 11, 2026, 17:15 PM -
A FINNISH NATIONWIDE OBESITY COHORT TO SUPPORT DATA-DRIVEN OBESITY CARE AND DRUG DEVELOPMENT
Aug 11, 2026, 17:15 PM -
GLOBAL VALUE ASSESSMENT FOR BIOLOGICS IN PSORIATIC ARTHRITIS IN THE TIME OF IRA AND MFN: DOES COST PER INCREMENTAL ACR50 RESPONDER ANALYSIS PROVIDE A CLINICALLY MEANINGFUL AND PRACTICAL CROSS-MARKET METRIC?
Aug 11, 2026, 17:15 PM -
KEY CONSIDERATIONS FOR SYNTHESIZING CROSS-COUNTRY ONCOLOGY RWE TRANSPORTABILITY STUDIES
Aug 11, 2026, 17:15 PM -
THE CHEERS CHECKLIST IN VACCINE ECONOMIC EVALUATION: A CRITICAL ANALYSIS FROM THE EPISTEMOLOGY OF COMMENSURABILITY
Aug 11, 2026, 17:15 PM -
A DECISION-QUESTION FRAMEWORK FOR PATIENT PREFERENCE EVIDENCE IN HTA AND HEOR
Aug 11, 2026, 17:15 PM -
WHY ADVANCED PSORIATIC ARTHRITIS THERAPIES ARE STOPPED AND SWITCHED, BY DRUG CLASS: EVIDENCE FROM US REAL-WORLD CLINICAL NOTES
Aug 11, 2026, 17:15 PM -
EVALUATING MULTI-INDICATION TECHNOLOGIES: IDENTIFYING WHICH PATIENT GROUPS BENEFIT MOST AND UNDER WHAT CONDITIONS?
Aug 11, 2026, 17:15 PM -
DEVELOPING A COMPREHENSIVE FRAMEWORK FOR GENERATING PATIENT EXPERIENCE DATA IN HEALTH ECONOMICS AND OUTCOMES RESEARCH TO SUPPORT BOTH REGULATORY AND HTA REQUIREMENTS
Aug 11, 2026, 17:15 PM -
ARE MEAS DELIVERING ON THEIR PROMISE? EVIDENCE FROM EU5 PAYER PERSPECTIVES
Aug 11, 2026, 17:15 PM -
HOW DOES FAILURE TO ACCOUNT FOR BEREAVEMENT COSTS AFFECT ECONOMIC EVALUATIONS?
Aug 11, 2026, 17:15 PM -
COST-MINIMIZATION ANALYSIS OF EFANESOCTOCOG ALFA VERSUS STANDARD HALF-LIFE FVIII CONCENTRATES FOR MAJOR SURGERY IN PATIENTS WITH MILD/MODERATE HEMOPHILIA A WITHOUT SELF-ADMINISTRATION CAPABILITY
Aug 11, 2026, 17:15 PM -
HYPERTENSION BURDEN AND PREDICTORS AMONG ADULTS RECEIVING SYSTEMIC CANCER THERAPY: A REAL-WORLD SINGLE-CENTER COHORT STUDY
Aug 11, 2026, 17:15 PM -
COMPARING COMPARISONS: CHARACTERISING THE EVIDENCE REQUIREMENTS FOR CLINICAL SIMILARITY UNDER THE NICE COST-COMPARISON ROUTE
Aug 11, 2026, 17:15 PM -
ARE QUALITY MEASURES MEASURING QUALITY? UNMASKING THE INFLUENCE OF CLINICAL AND SOCIAL RISK FACTORS
Aug 11, 2026, 17:15 PM -
A HYBRID HUMAN-AI ENHANCED NOMINAL GROUP TECHNIQUE FOR EVIDENCE-BASED POLICYMAKING: DEVELOPMENT AND REAL-WORLD APPLICATION OF POLISIS
Aug 11, 2026, 17:15 PM
